HSBC analyst Rajesh Kumar downgraded Novartis (NVS) to Reduce from Hold with a price target of CHF 82, down from CHF 95. The firm calls the shares as “value trap.” The company’s share repurchases and cost savings are a sign of a “lack of focus toward growth,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- PTC Therapeutics price target raised to $71 from $47 at UBS
- PTC Therapeutics price target raised to $70 from $52 at Baird
- PTC Therapeutics price target raised to $41 from $31 at BofA
- PTC Therapeutics’ Novartis deal expedites value creation, says Wells Fargo
- RBC upgrades PTC Therapeutics on ‘transformative’ Novartis deal